These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 36096824

  • 1. Reversal Of Arterial Disease by modulating Magnesium and Phosphate (ROADMAP-study): rationale and design of a randomized controlled trial assessing the effects of magnesium citrate supplementation and phosphate-binding therapy on arterial stiffness in moderate chronic kidney disease.
    Vermeulen EA, Eelderink C, Hoekstra T, van Ballegooijen AJ, Raijmakers P, Beulens JW, de Borst MH, Vervloet MG.
    Trials; 2022 Sep 12; 23(1):769. PubMed ID: 36096824
    [Abstract] [Full Text] [Related]

  • 2. A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
    Toussaint ND, Pedagogos E, Lioufas NM, Elder GJ, Pascoe EM, Badve SV, Valks A, Block GA, Boudville N, Cameron JD, Campbell KL, Chen SSM, Faull RJ, Holt SG, Jackson D, Jardine MJ, Johnson DW, Kerr PG, Lau KK, Hooi LS, Narayan O, Perkovic V, Polkinghorne KR, Pollock CA, Reidlinger D, Robison L, Smith ER, Walker RJ, Wang AYM, Hawley CM, IMPROVE-CKD Trial Investigators.
    J Am Soc Nephrol; 2020 Nov 12; 31(11):2653-2666. PubMed ID: 32917784
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of magnesium citrate, magnesium oxide and magnesium sulfate supplementation on arterial stiffness in healthy overweight individuals: a study protocol for a randomized controlled trial.
    Schutten JC, Joris PJ, Mensink RP, Danel RM, Goorman F, Heiner-Fokkema MR, Weersma RK, Keyzer CA, de Borst MH, Bakker SJL.
    Trials; 2019 May 28; 20(1):295. PubMed ID: 31138315
    [Abstract] [Full Text] [Related]

  • 6. The effect of magnesium supplementation on vascular calcification in chronic kidney disease-a randomised clinical trial (MAGiCAL-CKD): essential study design and rationale.
    Bressendorff I, Hansen D, Schou M, Kragelund C, Brandi L.
    BMJ Open; 2017 Jun 23; 7(6):e016795. PubMed ID: 28645983
    [Abstract] [Full Text] [Related]

  • 7. Effects of Magnesium Citrate, Magnesium Oxide, and Magnesium Sulfate Supplementation on Arterial Stiffness: A Randomized, Double-Blind, Placebo-Controlled Intervention Trial.
    Schutten JC, Joris PJ, Groendijk I, Eelderink C, Groothof D, van der Veen Y, Westerhuis R, Goorman F, Danel RM, de Borst MH, Bakker SJL.
    J Am Heart Assoc; 2022 Mar 15; 11(6):e021783. PubMed ID: 35253448
    [Abstract] [Full Text] [Related]

  • 8. Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.
    Lioufas N, Toussaint ND, Pedagogos E, Elder G, Badve SV, Pascoe E, Valks A, Hawley C, IMPROVE-CKD Writing Committee..
    BMJ Open; 2019 Feb 21; 9(2):e024382. PubMed ID: 30796122
    [Abstract] [Full Text] [Related]

  • 9. Control of metabolic predisposition to cardiovascular complications of chronic kidney disease by effervescent calcium magnesium citrate: a feasibility study.
    Quiñones H, Hamdi T, Sakhaee K, Pasch A, Moe OW, Pak CYC.
    J Nephrol; 2019 Feb 21; 32(1):93-100. PubMed ID: 30465137
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.
    Ruggiero B, Trillini M, Tartaglione L, Rotondi S, Perticucci E, Tripepi R, Aparicio C, Lecchi V, Perna A, Peraro F, Villa D, Ferrari S, Cannata A, Mazzaferro S, Mallamaci F, Zoccali C, Bellasi A, Cozzolino M, Remuzzi G, Ruggenenti P, Kohan DE, ANSWER Study Organization.
    Am J Kidney Dis; 2019 Sep 21; 74(3):338-350. PubMed ID: 31027883
    [Abstract] [Full Text] [Related]

  • 12. The Effect of Magnesium Supplementation on Vascular Calcification in CKD: A Randomized Clinical Trial (MAGiCAL-CKD).
    Bressendorff I, Hansen D, Schou M, Kragelund C, Svensson M, Hashemi B, Kristensen T, Vrist MH, Borg R, Tougaard B, Borg K, Hjortkjær HØ, Kristiansen CH, Carlson N, Nasiri M, Ashraf H, Pasch A, Brandi L.
    J Am Soc Nephrol; 2023 May 01; 34(5):886-894. PubMed ID: 36749131
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR).
    Tanaka A, Shibata H, Imai T, Yoshida H, Miyazono M, Takahashi N, Fukuda D, Okada Y, Teragawa H, Suwa S, Kida K, Moroi M, Taguchi I, Toyoda S, Shimabukuro M, Tanabe K, Tanaka K, Nangaku M, Node K, FIVE-STAR trial investigators.
    Cardiovasc Diabetol; 2023 Jul 31; 22(1):194. PubMed ID: 37525257
    [Abstract] [Full Text] [Related]

  • 15. A randomized control trial to assess the impact of vitamin D supplementation compared to placebo on vascular stiffness in chronic kidney disease patients.
    Levin A, Perry T, De Zoysa P, Sigrist MK, Humphries K, Tang M, Djurdjev O.
    BMC Cardiovasc Disord; 2014 Nov 07; 14():156. PubMed ID: 25381032
    [Abstract] [Full Text] [Related]

  • 16. Serum calcification propensity is associated with renal tissue oxygenation and resistive index in patients with arterial hypertension or chronic kidney disease.
    Pruijm M, Lu Y, Megdiche F, Piskunowicz M, Milani B, Stuber M, Bachtler M, Vogt B, Burnier M, Pasch A.
    J Hypertens; 2017 Oct 07; 35(10):2044-2052. PubMed ID: 28562422
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Associations of Serum Calciprotein Particle Size and Transformation Time With Arterial Calcification, Arterial Stiffness, and Mortality in Incident Hemodialysis Patients.
    Chen W, Fitzpatrick J, Monroy-Trujillo JM, Sozio SM, Jaar BG, Estrella MM, Serrano J, Anokhina V, Miller BL, Melamed ML, Bushinsky DA, Parekh RS.
    Am J Kidney Dis; 2021 Mar 07; 77(3):346-354. PubMed ID: 32800846
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.